Estela Rodriguez on CNS Activity of Tarlatamab in Small Cell Lung Cancer
Estela Rodriguez, Associate Director of Community Outreach-Thoracic Oncology and Co-Lead Thoracic Site Disease Group, Associate Director of Community Outreach at Sylvester Comprehensive Cancer Center, shared a post on X by Jarushka Naidoo, Full Professor and Consultant Medical Oncologist at Royal College of Surgeons in Irelan, adding:
“Truly exciting times for SCLC therapies – being able to offer BiTES and ADCs with CNS activity is a gamechanger (except the toxicity of these agents is real and requires patient selection).”
Quoting Jarushka Naidoo‘s post:
“CNS activity in BiTES and ADCs
Excellent talk from Bingnan Zhang, MD Anderson Cancer Center on intracranial response of untreated BM from tarlatamab in SCLC:
– 10 patients (9 BM, 1 LMD)
– icORR 90%
– selected responses rapid
Can we avoid WBRT in these patients?”
More posts featuring Estela Rodriguez and Jarushka Naidoo on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023